178 related articles for article (PubMed ID: 32868386)
21. CYP2C9, but not CYP2C19, polymorphisms affect the pharmacokinetics and pharmacodynamics of glyburide in Chinese subjects.
Yin OQ; Tomlinson B; Chow MS
Clin Pharmacol Ther; 2005 Oct; 78(4):370-7. PubMed ID: 16198656
[TBL] [Abstract][Full Text] [Related]
22. Clinical significance of CYP2C9-status guided valproic acid therapy in children.
Bűdi T; Tóth K; Nagy A; Szever Z; Kiss Á; Temesvári M; Háfra E; Garami M; Tapodi A; Monostory K
Epilepsia; 2015 Jun; 56(6):849-55. PubMed ID: 25967074
[TBL] [Abstract][Full Text] [Related]
23. Genetic polymorphisms of CYP2C9, CYP2C19, and CYP3A5 in Kosovar population.
Krasniqi V; Dimovski A; Bytyqi HQ; Eftimov A; Šimičević L; Božina N
Arh Hig Rada Toksikol; 2017 Sep; 68(3):180-184. PubMed ID: 28976882
[TBL] [Abstract][Full Text] [Related]
24. Genetic Polymorphism of Drug-Metabolizing Enzymes CYP2C9 and CYP2C19 in Moroccan Population.
Afilal D; Basselam MA; Brakez Z; Chouham S; Brehm A; Izaabel EH
Genet Test Mol Biomarkers; 2017 May; 21(5):298-304. PubMed ID: 28282224
[TBL] [Abstract][Full Text] [Related]
25. Impact of MDR1 and UGT Gene Polymorphisms on Sodium Valproate Plasma Concentration in Patients with Epilepsy.
Song C; Li X; Zhang H; Bao J; Lu W; Peng Q; Zhang Y
Clin Lab; 2022 Oct; 68(10):. PubMed ID: 36250837
[TBL] [Abstract][Full Text] [Related]
26. The association between CYP2C9/2C19 polymorphisms and phenytoin maintenance doses in Asian epileptic patients: A systematic review and meta-analysis
.
Liao K; Liu Y; Ai CZ; Yu X; Li W
Int J Clin Pharmacol Ther; 2018 Jul; 56(7):337-346. PubMed ID: 29628024
[TBL] [Abstract][Full Text] [Related]
27. Influence of uridine diphosphate glucuronosyltransferase 2B7 -161C>T polymorphism on the concentration of valproic acid in pediatric epilepsy patients.
Inoue K; Suzuki E; Yazawa R; Yamamoto Y; Takahashi T; Takahashi Y; Imai K; Koyama S; Inoue Y; Tsuji D; Hayashi H; Itoh K
Ther Drug Monit; 2014 Jun; 36(3):406-9. PubMed ID: 24365988
[TBL] [Abstract][Full Text] [Related]
28. The effect of genetic polymorphisms of cytochrome P450 CYP2C9, CYP2C19, and CYP2D6 on drug-resistant epilepsy in Turkish children.
Seven M; Batar B; Unal S; Yesil G; Yuksel A; Guven M
Mol Diagn Ther; 2014 Apr; 18(2):229-36. PubMed ID: 24338437
[TBL] [Abstract][Full Text] [Related]
29. Genetic polymorphisms and valproic acid plasma concentration in children with epilepsy on valproic acid monotherapy.
Mei S; Feng W; Zhu L; Yu Y; Yang W; Gao B; Wu X; Zhao Z; Fang F
Seizure; 2017 Oct; 51():22-26. PubMed ID: 28763744
[TBL] [Abstract][Full Text] [Related]
30. VARIANTS OF THE FORMATION AND COURSE OF DRUG-RESISTANT EPILEPSY IN CHILDREN WITH GENETIC POLYMORPHISMS OF CYP2C9, CYP2C19, CYP3A4.
Tantsura LM; Pylypets OY; Tretiakov DV; Tantsura YO
Wiad Lek; 2023; 76(5 pt 1):1007-1013. PubMed ID: 37326083
[TBL] [Abstract][Full Text] [Related]
31. Associations of CYP2C9 and CYP2A6 Polymorphisms with the Concentrations of Valproate and its Hepatotoxin Metabolites and Valproate-Induced Hepatotoxicity.
Zhao M; Zhang T; Li G; Qiu F; Sun Y; Zhao L
Basic Clin Pharmacol Toxicol; 2017 Aug; 121(2):138-143. PubMed ID: 28273397
[TBL] [Abstract][Full Text] [Related]
32. CYP2C9 (*2&*3) and CYP2C19 (*2&*3) polymorphisms among children with nonlesional epilepsy: a single-center study.
Eltalal S; El Ayouty M; El-Said A; Wahba Y
Acta Neurol Belg; 2021 Dec; 121(6):1623-1631. PubMed ID: 32683556
[TBL] [Abstract][Full Text] [Related]
33. Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Iranian population.
Zand N; Tajik N; Moghaddam AS; Milanian I
Clin Exp Pharmacol Physiol; 2007; 34(1-2):102-5. PubMed ID: 17201743
[TBL] [Abstract][Full Text] [Related]
34. CYP2C19 & UGT1A6 genetic polymorphisms and the impact on Valproic acid-induced weight gain in people with epilepsy: Prospective genetic association study.
Mani B; Nair PP; Sekhar A; Kamalanathan S; Narayan SK; Kesavan R
Epilepsy Res; 2021 Nov; 177():106786. PubMed ID: 34656038
[TBL] [Abstract][Full Text] [Related]
35. Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations.
Allabi AC; Gala JL; Desager JP; Heusterspreute M; Horsmans Y
Br J Clin Pharmacol; 2003 Dec; 56(6):653-7. PubMed ID: 14616425
[TBL] [Abstract][Full Text] [Related]
36. Cytochrome P450 2C19 enzyme, Cytochrome P450 2C9 enzyme, and Cytochrome P450 2D6 enzyme allelic variants and its possible effect on drug metabolism: A retrospective study.
Naujokaitis D; Asmoniene V; Kadusevicius E
Medicine (Baltimore); 2021 Mar; 100(11):e24545. PubMed ID: 33725937
[TBL] [Abstract][Full Text] [Related]
37. Influence of CYP2C9 polymorphism on metabolism of valproate and its hepatotoxin metabolite in Iranian patients.
Amini-Shirazi N; Ghahremani MH; Ahmadkhaniha R; Mandegary A; Dadgar A; Abdollahi M; Shadnia S; Pakdaman H; Kebriaeezadeh A
Toxicol Mech Methods; 2010 Oct; 20(8):452-7. PubMed ID: 20602621
[TBL] [Abstract][Full Text] [Related]
38. Genetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population.
Arvanitidis K; Ragia G; Iordanidou M; Kyriaki S; Xanthi A; Tavridou A; Manolopoulos VG
Fundam Clin Pharmacol; 2007 Aug; 21(4):419-26. PubMed ID: 17635181
[TBL] [Abstract][Full Text] [Related]
39. Neurological toxicity after phenytoin infusion in a pediatric patient with epilepsy: influence of CYP2C9, CYP2C19 and ABCB1 genetic polymorphisms.
Dorado P; López-Torres E; Peñas-Lledó EM; Martínez-Antón J; Llerena A
Pharmacogenomics J; 2013 Aug; 13(4):359-61. PubMed ID: 22641027
[TBL] [Abstract][Full Text] [Related]
40. Cytochrome P450 2C19 polymorphisms and valproic acid-induced weight gain.
Noai M; Soraoka H; Kajiwara A; Tanamachi Y; Oniki K; Nakagawa K; Ishitsu T; Saruwatari J
Acta Neurol Scand; 2016 Mar; 133(3):216-23. PubMed ID: 26223287
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]